Analyst Ratings January 23, 2026

Roth/MKM Launches Buy Coverage on Insmed with $212 Price Objective

Analysts highlight robust drug performance and pipeline potential amid current unprofitability

By Sofia Navarro INSM
Roth/MKM Launches Buy Coverage on Insmed with $212 Price Objective
INSM

Roth/MKM has initiated a Buy rating on Insmed (NASDAQ:INSM), setting a $212 price target that indicates significant potential appreciation from present levels. The firm's analysis points to the strong future prospects of Insmed's Brinsupri and Arikayce therapies, underpinned by favorable trial expectations and market adoption. Despite recent revenues of $447 million, Insmed remains unprofitable with negative EBITDA, but its pipeline contributes substantial optionality.

Key Points

  • Roth/MKM initiates Buy rating on Insmed with $212 price target, reflecting around 32% upside from current levels.
  • Strong sales performance of Brinsupri and anticipated positive Phase 3 ENCORE trial result could significantly boost revenues, especially for the frontline use of Arikayce.
  • Despite unprofitability, Insmed’s portfolio and pipeline, including TPIP adding $5 billion in optionality, underpin the favorable analyst outlook and expansion potential.

On Friday, the financial research group Roth/MKM commenced coverage of Insmed Incorporated, assigning the biotechnology firm a Buy rating accompanied by a price target of $212.00. This target assumes a sizeable increase above the closing price of $160.39, a level where the shares have already nearly doubled over the previous year, with a 106% gain as per InvestingPro metrics.

Roth/MKM's endorsement is largely based on the optimistic outlook for Insmed’s portfolio heading into 2026, particularly spotlighting the Brinsupri drug. The firm projects peak sales for Brinsupri to exceed consensus expectations by about 13% according to Visible Alpha data. This upbeat stance is despite the company not yet achieving profitability; the 12-month trailing period shows reported revenue at $447 million contrasted by an EBITDA deficit close to $978.79 million, highlighting operational losses.

Integral to Roth/MKM’s positive view is the Phase 3 ENCORE clinical trial, for which they assign a 75% likelihood of success. The final results of this trial, anticipated in March or April, could potentially unlock additional revenues for the frontline treatment Arikayce estimated at $1.3 billion, which would be a significant boost to the company’s top line.

On the risk front, Roth/MKM classifies the brensocatib CEDAR trial for hidradenitis suppurativa as high risk. Nonetheless, the firm notes that the previous failure in the CRS-sNP indication has adjusted market expectations downward ahead of a second-quarter 2026 data readout, effectively improving the risk-return alignment for investors.

Furthermore, the research note highlights that TPIP contributes an added $5 billion in pipeline opportunity, enhancing the overall valuation and reinforcing the Buy rating with an anticipated return of approximately 35%. From a financial health perspective, InvestingPro’s analysis indicates that Insmed's shares currently trade above the estimated fair value despite robust fundamentals including a solid current ratio of 4.63 and manageable debt levels, underscoring balance sheet resilience amid expansion.

Additional insights and detailed analytical research are available through InvestingPro’s Pro Research Report, aiding investors to navigate the complex biotech landscape with well-rounded information.

In related developments, Insmed announced fourth-quarter 2025 sales for Brinsupri totaled $144.6 million, surpassing analyst expectations by a substantial margin of 116%. This impressive uptake has led RBC Capital Markets to elevate its price target for the stock to $200 while maintaining an Outperform rating, reflecting confidence in continued growth.

Moreover, the company’s established product ARIKAYCE posted unaudited global revenue approximating $433.8 million for 2025, marking a 19% year-over-year increase. The company anticipates ARIKAYCE revenues in the range of $450 million to $470 million for 2026, reflecting its expanding market presence. RBC’s target adjustment incorporates enhanced penetration estimates for Brinsupri’s uptake in the last quarter of 2025.

These early revenue results illustrate Insmed’s strong market foothold with Brinsupri’s recent launch and better-than-expected performance from ARIKAYCE, highlighting a positive growth trajectory for the firm.

Risks

  • High risk associated with brensocatib CEDAR trial for hidradenitis suppurativa, adding clinical development uncertainty.
  • Current unprofitability reflected by negative EBITDA despite solid revenue figures may impact financial stability or investor sentiment.
  • The previous failure in CRS-sNP indication affects market expectations and introduces uncertainty ahead of next trial readout in 2026.

More from Analyst Ratings

KeyBanc Keeps Cautious View on LyondellBasell After Difficult Quarter, Cites Cash-Flow Limits vs. Dividend Feb 2, 2026 KeyBanc Sticks with Overweight on Murphy USA, Sees Near-Term Upside as Fuel Margins Improve Feb 2, 2026 KeyBanc Stands by Overweight Call on AppFolio, Flags ARPU and Product Drivers for 2026 Feb 2, 2026 KeyBanc Sticks With Overweight on Eastman; $74 Target Reflects Modest Upside Feb 2, 2026 Bernstein Boosts SanDisk Price Target to $1,000 After Robust Q2; Peers Follow Suit Feb 2, 2026